Equity research analysts tracking Stereotaxis (NYSE American: STXS) maintain a generally positive consensus rating leaning toward a Buy or Strong Buy, with average 12-month price targets spanning between $3.00 and $3.50 per share. Financial projections reflect anticipated revenue growth driven by commercial adoption of its newly approved robotic ablation catheters and expanding hospital installations, though analysts continue to monitor ongoing operating losses and small-cap market volatility.